FUB-APINACA

FUB-APINACA (also known as AFUBINACA and FUB-AKB48) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1] It is an analog of APINACA and 5F-APINACA where the pentyl chain has been replaced with fluorobenzyl.

FUB-APINACA
Legal status
Legal status
Identifiers
IUPAC name
  • N-(Adamantan-1-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H26FN3O
Molar mass403.501 g·mol−1
3D model (JSmol)
SMILES
  • O=C(NC1(C[C@H]2C3)C[C@H]3C[C@H](C2)C1)C4=NN(CC5=CC=C(F)C=C5)C6=C4C=CC=C6
InChI
  • InChI=1S/C25H26FN3O/c26-20-7-5-16(6-8-20)15-29-22-4-2-1-3-21(22)23(28-29)24(30)27-25-12-17-9-18(13-25)11-19(10-17)14-25/h1-8,17-19H,9-15H2,(H,27,30)/t17-,18+,19-,25?
  • Key:MWBHSNBPUSKVDD-LPSAYFBNSA-N

Pharmacology

FUB-APINACA acts as a full agonist with a binding affinity of 1.06 nM at CB1 and 0.174 nM at CB2 cannabinoid receptors.[2]

In the United States, FUB-APINACA was temporarily emergency scheduled by the DEA in 2019.[3] and made a permanent Schedule I Controlled Substance nationwide on April 7, 2022.[4] Previously, it was illegal only in Alabama (listed as FUB-AKB48).[5]

Sweden's public health agency suggested classifying FUB-APINACA as a hazardous substance on November 10, 2014.[6]

See also

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.